AVEO - AVEO Pharmaceuticals, Inc.
0.7000 0.00 (0.00%)
After hours: 5:30PM EDT
| Previous Close | 0.7048 |
| Open | 0.7140 |
| Bid | 0.6900 x 1300 |
| Ask | 0.7000 x 800 |
| Day's Range | 0.6733 - 0.7140 |
| 52 Week Range | 0.4900 - 3.5900 |
| Volume | 1,413,327 |
| Avg. Volume | 7,085,527 |
| Market Cap | 112.517M |
| Beta (3Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1790 |
| Earnings Date | May 11, 2017 - May 12, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.75 |
- Business Wire•6 days ago
AVEO Oncology Announces Presentations at the 2019 ASCO Annual Meeting
AVEO Oncology today announced two poster presentations at the upcoming American Society of Clinical Oncology Annual Meeting being held May 31-June 4, 2019 in Chicago, Illinois.
- Zacks•11 days ago
AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark
AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
- Zacks•13 days ago
AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Tops Revenue Estimates
AVEO (AVEO) delivered earnings and revenue surprises of -20.00% and 117.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•13 days ago
AVEO: 1Q Earnings Snapshot
The Cambridge, Massachusetts-based company said it had net income of 6 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- Business Wire•13 days ago
AVEO Reports First Quarter 2019 Financial Results and Provides Business Update
AVEO Oncology today reported financial results for the first quarter ended March 31, 2019 and provided a business update.
- Zacks•14 days ago
AVEO Pharmaceuticals (AVEO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•20 days ago
AVEO Pharmaceuticals (AVEO) Dips More Than Broader Markets: What You Should Know
In the latest trading session, AVEO Pharmaceuticals (AVEO) closed at $0.91, marking a -1.42% move from the previous day.
- Business Wire•21 days ago
AVEO Oncology to Participate in the 5th Annual SunTrust Robinson Humphrey Life Sciences Summit
AVEO Oncology (AVEO) today announced that members of the management team will participate in the 5th Annual SunTrust Robinson Humphrey Life Sciences Summit on Wednesday, May 8, 2019. AVEO Pharmaceuticals, Inc. (the “Company” or “AVEO”) is a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. The Company is working to develop and commercialize its lead candidate tivozanib in North America as a treatment for RCC.
- Zacks•21 days ago
AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up?
During AVEO Pharmaceuticals' (AVEO) Q1 conference call, investor focus will be on its NDA submission for Fotivda in the United States pertaining to the treatment of advanced or metastatic RCC.
- Business Wire•26 days ago
FRIDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AVEO Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AVEO Pharmaceuticals, Inc. (“AVEO” or “the Company”) (NASDAQ: AVEO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- GlobeNewswire•26 days ago
APRIL 26 DEADLINE: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AVEO Pharmaceuticals, Inc. (AVEO) and Encourages AVEO Investors Who Suffered Losses Exceeding $100,000 to Contact the Firm
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired AVEO Pharmaceuticals, Inc. (AVEO) securities between August 4, 2016 and January 31, 2019 (the “Class Period”). Investors have until April 26, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- ACCESSWIRE•26 days ago
CLASS ACTION UPDATE for AVEO, AAPL and S: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / April 25, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
- ACCESSWIRE•26 days ago
FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 25, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AVEO Pharmaceuticals, Inc. (''AVEO'' ...
- GlobeNewswire•26 days ago
CLASS ACTION UPDATE for CORT, AVEO, NIO and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, April 25, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
- ACCESSWIRE•27 days ago
Final Deadline DPLO & AVEO Bronstein, Gewirtz & Grossman, LLC
NEW YORK, NY / ACCESSWIRE / April 25, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...
- GlobeNewswire•27 days ago
FRIDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AVEO Pharmaceuticals, Inc. (“AVEO” or “the Company”) (NASDAQ: AVEO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between August 4, 2016 and January 31, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before April 26, 2019. According to the Complaint, the Company made false and misleading statements to the market.
- ACCESSWIRE•27 days ago
CLASS ACTION UPDATE for AVEO, KHC and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / April 24, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
- ACCESSWIRE•27 days ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AVEO, INGN and NTNX
NEW YORK, NY / ACCESSWIRE / April 24, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have ...
- ACCESSWIRE•28 days ago
APRIL 26 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 23, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AVEO Pharmaceuticals, Inc. (''AVEO'' ...
- ACCESSWIRE•28 days ago
CLASS ACTION UPDATE for AVEO, DPLO and S: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / April 23, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
- GlobeNewswire•28 days ago
AVEO FRIDAY DEADLINE ALERT: Rosen Law Firm Reminds AVEO Pharmaceuticals, Inc. Investors of Important April 26th Deadline in Securities Class Action Lawsuit – AVEO
NEW YORK, April 23, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from August 4,.
- ACCESSWIRE•28 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aveo Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – AVEO
NEW YORK, NY / ACCESSWIRE / April 23, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against Aveo Pharmaceuticals, Inc. (''Aveo'' or the ''Company'') (AVEO) and certain of its officers and directors. The class action, filed in United States District Court, Southern District of New York, and indexed under 19-cv-01722, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise acquired AVEO securities between August 4, 2016 through January 31, 2019, both dates inclusive (the ''Class Period''), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the ''Exchange Act'') and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- Business Wire•28 days ago
AVEO Oncology Announces $2M Milestone Payment From EUSA Pharma Related To Commercialization of FOTIVDA® in Spain
AVEO Oncology (AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the reimbursement approval and commercial launch in Spain of FOTIVDA® (tivozanib) as a first line treatment of adult patients with advanced renal cell carcinoma (RCC). Commercial launch in Spain is the third of five EU5 country launches to trigger a $2 million payment under the terms of AVEO’s license agreement with EUSA Pharma.
